Eszopiclone

Introduction Overview

Generic Name

eszopiclone

Brand Name

Lunesta

Dosage Form

oral tablet (1 mg, 2 mg, 3 mg)

Drug Class

Miscellaneous anxiolytics, sedatives and hypnotics (non-benzodiazepine sedative-hypnotic)

Pharmacokinetics

Absorption:
Eszopiclone is rapidly absorbed after oral administration, with onset of action typically within 30 minutes. Peak plasma concentrations (Cmax) are generally reached within 1 hour post-dose under fasting conditions. Food intake, especially high-fat or heavy meals, can delay absorption significantly and reduce the rate at which plasma concentrations rise, though the total bioavailability is not substantially altered. This delay in absorption may diminish the hypnotic efficacy when Lunesta is taken with or shortly after meals, thus clinical guidelines recommend administration immediately before bedtime on an empty stomach to maximize the onset of the sedative effect.

Distribution:
Eszopiclone exhibits moderate plasma protein binding, approximately 52% to 59%, binding primarily to albumin. Its volume of distribution (Vd) is reported to be about 1.7 L/kg, indicating extensive distribution into body tissues, including the central nervous system (CNS). The drug readily crosses the blood-brain barrier to exert its pharmacodynamic effects on GABA receptors in the brain. In elderly patients or those with hepatic impairment, alterations in distribution parameters can occur, potentially affecting drug levels and duration of action.

Metabolism:
Eszopiclone undergoes extensive hepatic metabolism primarily via the cytochrome P450 system, with CYP3A4 playing a significant role. The metabolism involves oxidation and demethylation to inactive metabolites, which lack pharmacologic activity. Additionally, UGT (uridine diphosphate-glucuronosyltransferase) enzymes contribute to minor pathways of conjugation. First-pass metabolism reduces systemic availability, necessitating oral administration of effective doses. Factors affecting hepatic enzyme activity, such as concomitant medications or hepatic impairment, can alter plasma concentrations and clinical response.

Elimination:
The elimination half-life of eszopiclone is approximately 6 hours, allowing once-daily dosing at bedtime. The metabolites are primarily excreted via the kidneys; about 50% to 60% of the drug-related material is recovered in the urine, mainly as metabolites, and about 14% in feces. Renal impairment can reduce clearance, warranting careful dose adjustments or monitoring. The relatively predictable elimination kinetics contribute to the drug's safety profile when used as directed, but accumulation can occur in patients with severe renal or hepatic dysfunction.

Dosage Forms

Available Dosage Forms:
Lunesta is available exclusively as oral tablets in three strengths: 1 mg, 2 mg, and 3 mg. These film-coated tablets contain eszopiclone as the active ingredient along with inactive excipients including calcium phosphate, colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, titanium dioxide, triacetin, and for the 1 mg and 3 mg tablets, FD&C Blue #2.

Dosages for Adults and Adolescents:
The recommended starting dose for adults with insomnia is 1 mg taken orally once daily immediately before bedtime. If the patient does not achieve adequate sleep improvement after 7 to 10 days, the dose may be increased to 2 mg and then to the maximum of 3 mg per day based on efficacy and tolerability. The dose titration should be cautious to minimize next-day sedation or impairment. Lunesta is not approved for use in patients under 18 years of age, and thus no adolescent dosing is recommended.

Specific Patient Populations:
In geriatric patients or those with compromised hepatic function, the initial recommended dose is 1 mg once daily at bedtime, with a cautious titration not to exceed 2 mg per day due to increased sensitivity and risk of prolonged sedation. Patients with renal impairment may require monitoring for increased drug exposure. The drug is contraindicated in patients with known hypersensitivity, history of complex sleep behaviors, or concurrent use with other CNS depressants unless under strict medical supervision.

Mechanism Of Action

Eszopiclone, the active ingredient in Lunesta, acts primarily by modulating the gamma-aminobutyric acid (GABA) neurotransmitter system, the chief inhibitory pathway within the central nervous system. It binds selectively to the benzodiazepine site on the GABA-A receptor complex, which results in enhanced affinity of GABA for its receptor and increased frequency of chloride channel opening. This hyperpolarizes neurons, slowing neuronal firing and promoting sedative and hypnotic effects beneficial for initiating and maintaining sleep.

Unlike classical benzodiazepines, eszopiclone exhibits a more selective binding profile, primarily targeting GABA-A receptor subtypes containing the alpha1 subunit, known to mediate sedative and hypnotic properties, rather than anxiolytic or muscle relaxant effects associated with other subunits. This selective action contributes to improved efficacy and a potentially more favorable side effect profile regarding anxiolysis and muscle relaxation compared to benzodiazepines.

At the cellular level, eszopiclone prolongs inhibitory postsynaptic potentials, dampening neuronal excitability directly involved in the sleep-wake cycle regulation. Clinical studies indicate that eszopiclone can reduce sleep latency and increase total sleep time, effectively improving sleep architecture with minimal disruption to REM sleep compared to some other hypnotics.

Research has demonstrated that the hypnotic effects of eszopiclone are dose-dependent, with efficacy observed at doses as low as 1 mg. Clinical trials comparing eszopiclone to other non-benzodiazepine hypnotics such as zolpidem have shown comparable efficacy but with a longer duration of action, which translates to sustained sleep maintenance benefits. The drug's pharmacodynamic properties, combined with its controlled Schedule IV classification, reflect its potential for dependence, necessitating careful clinical use.

Pharmacological Actions

Enhances GABAergic neurotransmission via selective binding to the benzodiazepine site on the GABA-A receptor complex
Induces sedation and hypnosis by slowing CNS neuronal activity
Reduces sleep latency and increases total sleep duration in patients with insomnia
Promotes sleep maintenance with minimal disruption of normal sleep architecture including REM sleep
Exhibits anxiolytic-like effects due to central nervous system depressant actions
Possesses muscle relaxant and anticonvulsant properties to a lesser extent than classical benzodiazepines
Has dose-dependent hypnotic efficacy with an established safety margin
Exerts effects without significant metabolic active metabolites, reducing prolonged sedation risk
Demonstrates less tolerance development compared to traditional benzodiazepines with short-term use
Classified as a Schedule IV controlled substance due to potential for abuse and dependence
Produces cognitive and psychomotor impairment that can impair activities requiring alertness, such as driving
Can cause complex sleep behaviors including sleepwalking and sleep-driving in susceptible individuals

Therapeutic Or Clinical Uses

Treatment of insomnia, including difficulty falling asleep and frequent nighttime awakenings
Improves sleep onset latency and overall sleep maintenance
Management of chronic insomnia with demonstrated efficacy up to 12 months in clinical studies
Alternative hypnotic agent for patients who cannot tolerate benzodiazepines
Adjunctive agent in the treatment of sleep disorders related to psychiatric conditions such as depression-associated insomnia
Facilitates full restorative sleep necessary for daytime functioning and mental health
Used in elderly patients with insomnia at lower doses to reduce risk of falls and next-day sedation
Occasionally utilized off-label for sleep disturbances in conditions such as restless legs syndrome
Provides an option for patients with prior history of benzodiazepine dependence due to distinct pharmacologic profile
Supports replacement therapy for patients transitioning from other sedative-hypnotics
May be considered for short-term insomnia treatment pending clinical assessment
Used when non-pharmacologic therapies such as cognitive behavioral therapy for insomnia (CBT-I) are insufficient

Side Or Adverse Effects

Unpleasant metallic or bitter taste persisting after dosing
Daytime drowsiness or residual sedation leading to impaired alertness
Dizziness, which may increase fall risk especially in elderly patients
Headache occurring within hours post-dose
Dry mouth
Symptoms resembling common cold such as nasal congestion or sore throat
Complex sleep behaviors including sleepwalking, sleep-driving, and performing activities while not fully awake
Amnesia or memory impairment occurring especially if the drug is taken without allowing sufficient sleep duration
Confusion or hallucinations, particularly in patients with psychiatric history
Worsening of depression and emergence of suicidal ideation in predisposed patients
Withdrawal symptoms including anxiety, agitation, and insomnia upon abrupt discontinuation after chronic use
Hypersensitivity reactions including rash, hives, swelling, or anaphylaxis in rare cases
Potential for dependence and abuse with prolonged or unsupervised use
Gastrointestinal discomfort such as nausea or vomiting in rare cases
Impaired coordination and psychomotor performance affecting activities such as driving

Precautions

Use with caution in elderly patients due to increased sensitivity and risk of falls or fractures
Avoid combining with alcohol or other CNS depressants to minimize risk of respiratory depression and excessive sedation
Do not take unless able to dedicate 7 to 8 hours for uninterrupted sleep to prevent next-day impairment
Assess for suicidal thoughts or worsening depression prior to and during treatment especially in patients with psychiatric history
Avoid use in patients with known hypersensitivity to eszopiclone or formulation excipients
Do not use concomitantly with other sedatives unless recommended by a healthcare professional
Administer immediately before bedtime on an empty stomach for optimal pharmacokinetics
Exercise caution or dose adjustment may be needed in patients with hepatic or renal impairment
Avoid abrupt discontinuation to prevent withdrawal and rebound insomnia; taper dosage under medical supervision
Advise patients about potential for complex sleep-related behaviors and to report any unusual activities immediately
Pregnancy or breastfeeding women should use only if clearly needed and after consultation with healthcare provider
Monitor for signs of misuse or dependence especially in patients with history of substance abuse
Avoid use in pediatric populations under 18 years of age due to lack of established safety and efficacy
Be vigilant for cognitive or psychomotor impairment impacting activities requiring full alertness
Store securely to prevent unauthorized use and potential abuse

Warnings

Boxed Warning for Complex Sleep Behaviors that may result in serious injury or death including sleep-driving, sleep-eating, and other activities performed while not fully awake
Potential for next-day psychomotor impairment affecting ability to operate vehicles or machinery safely
Risk of worsening depression, suicidal ideation, and aggressive behavior in susceptible individuals
Contraindicated in patients with known history of complex sleep behaviors associated with Lunesta or similar hypnotics
Risk of dependence, withdrawal symptoms, and potential for abuse with chronic use
Avoid concomitant use with other CNS depressants to prevent respiratory depression and fatal overdose
Do not consume alcohol during treatment as it potentiates sedative and respiratory depressant effects
Amnesia and cognitive impairment may occur if drug is taken without allowing adequate sleep time
May cause severe allergic reactions including anaphylaxis necessitating emergency medical treatment
Use with caution in patients with respiratory disorders such as sleep apnea, COPD, or asthma
Not recommended for long-term use without periodic reevaluation due to unclear safety profile beyond 12 months
Avoid use in pregnancy and breastfeeding unless benefits outweigh risks after careful assessment
Sudden discontinuation can precipitate rebound insomnia and withdrawal symptoms
Overdose can be fatal especially when combined with other CNS depressants or opioids
Patients should be counseled to store medication securely to prevent misuse or accidental ingestion

Contraindication

Hypersensitivity to eszopiclone or any component of the formulation
History of complex sleep behaviors such as sleep-driving, sleep-eating, or sleepwalking induced by Lunesta or other sedative-hypnotics
Concomitant use of alcohol or other CNS depressants that significantly increase sedation
Patients who cannot dedicate a full night's sleep (7-8 hours) as required for safe drug use
Children and adolescents younger than 18 years due to insufficient safety and efficacy data
Severe hepatic impairment due to increased systemic exposure and prolonged sedation
Known or suspected pregnancy unless potential benefits justify the potential fetal risk
Previous history of substance abuse or dependence without close medical supervision
Concurrent use with other sedatives, opioids, or medications causing respiratory depression unless closely monitored
Patients with sleep apnea or severe respiratory insufficiency without medical clearance and caution
Severe psychotic illness or unstable psychiatric conditions where CNS depressant effects may exacerbate symptoms

Drug Interactions

Additive sedation and respiratory depression with concomitant use of opioids, benzodiazepines, barbiturates, or other CNS depressants
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase eszopiclone plasma concentrations leading to enhanced effects and toxicity
CYP3A4 inducers (e.g., rifampin, carbamazepine) can reduce eszopiclone levels, decreasing hypnotic efficacy
Alcohol consumption potentiates sedative effects and risk of complex sleep behaviors and respiratory depression
Use with muscle relaxants, antipsychotics, antihistamines, antidepressants, or anticonvulsants may have synergistic CNS depressant effects
Avoid combination with other sleep medications such as zolpidem or temazepam without medical supervision
Caution when co-administered with drugs that impair cognitive function or psychomotor coordination
Co-administration with fluvoxamine or other potent CYP enzyme inhibitors requires dose adjustment
Monitoring is recommended when used with drugs affecting hepatic metabolism to avoid accumulation
Interactions may lead to increased risk of next-day impairment and sedation requiring dose modification
Concomitant use of eszopiclone with valproic acid or phenytoin may alter pharmacokinetics necessitating close observation
Use with serotonergic drugs may rarely increase risk of neuropsychiatric adverse effects
Interactions with herbal supplements like kava, valerian, or melatonin can potentiate sedative effects
Careful consideration is needed when combined with antihypertensives that may cause dizziness or syncope
Patients should disclose all medications including over-the-counter drugs and supplements before initiating Lunesta

Preparations Of The Drug

Oral film-coated tablets containing eszopiclone in strengths of 1 mg, 2 mg, and 3 mg
Tablets include inactive ingredients such as calcium phosphate, colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, titanium dioxide, and triacetin
1 mg and 3 mg tablets contain FD&C Blue #2 as a coloring agent
Prepared for oral administration immediately at bedtime to optimize rapid onset
Available in blister packs and bottles for prescription dispensing
Manufactured by Waylis Therapeutics LLC with strict quality control to ensure potency and stability
Tablets should be stored at room temperature, away from moisture and heat, and kept securely to avoid misuse
Sold under brand name Lunesta as well as in generic formulation containing eszopiclone
Formulated to provide consistent bioavailability and predictable pharmacokinetics
Packaging may include child-resistant features to prevent accidental ingestion
Intended for short-term or long-term insomnia management as per prescribing information
Labeled for prescription use only due to Schedule IV controlled substance classification
Supplied with patient information leaflets detailing use, side effects, and precautions
Regular batch testing conducted to ensure absence of impurities or degradation
No available intravenous or alternative routes of administration; oral tablet is sole marketed form